PAVmed Inc. (PAVM) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

PAVmed Inc. (PAVM) Healthcare & Pipeline Overview

PAVmed Inc. is a medical device company specializing in innovative solutions for early cancer detection and minimally invasive treatments. Their portfolio, featuring EsoCheck and CarpX, addresses significant unmet needs in esophageal health and carpal tunnel syndrome, positioning them for growth in the medical device sector.

What Is the Investment Thesis for PAVM?

PAVmed's investment thesis centers on its innovative medical device portfolio targeting large, underserved markets. Key value drivers include the commercial success of EsoCheck and EsoGuard in early esophageal cancer detection, and CarpX in carpal tunnel treatment. The company's growth catalysts involve expanding market penetration for existing products and advancing its pipeline of novel devices, such as PortIO and Veris. A critical factor is PAVmed's ability to secure regulatory approvals and reimbursement coverage for its products. The company's high profit margin of 564.8% indicates potential for profitability if revenue scales. However, the negative gross margin of -291.5% raises concerns about cost management. Successful execution of clinical trials and strategic partnerships are crucial for realizing PAVmed's long-term value.

Based on FMP financials and quantitative analysis

PAVM Key Highlights

CarpX is a percutaneous device to treat carpal tunnel syndrome, offering a minimally invasive alternative to traditional surgery.

• EsoCheck is an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE).
• EsoGuard, a bisulfite-converted next-generation sequencing DNA assay, complements EsoCheck by providing advanced diagnostic capabilities.
• PAVmed's product pipeline includes EsoCure, an esophageal ablation device to treat dysplastic BE.
• The company's high profit margin of 564.8% suggests potential profitability if revenue scales.

Who Are PAVM's Competitors?

PAVM is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PAVM's Key Strengths?

Innovative medical device portfolio.

• Proprietary technologies with patent protection.
• Focus on unmet medical needs.
• High profit margin

What Are PAVM's Weaknesses?

Negative gross margin

• Limited commercialization experience.
• Dependence on regulatory approvals.
• Small size and limited resources.

What Could Drive PAVM Stock Higher?

FDA clearance for PortIO, expanding vascular access options.

• Increasing market penetration of EsoCheck and EsoGuard for early esophageal cancer detection.
• Commercialization and adoption of CarpX for carpal tunnel syndrome treatment.
• Clinical trial results for Veris platform, showcasing remote monitoring capabilities.

What Are the Key Risks for PAVM?

Financial-distress signal — its Altman Z-Score of -9.66 sits in the distress zone (elevated bankruptcy risk).

• Negative return on equity (-49.7%) — the business is not currently generating profit on shareholder capital.
• Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
• Regulatory delays in obtaining approvals for new products.
• Competition from established medical device companies.
• Reimbursement challenges from healthcare payers.
• Product liability claims and litigation.
• Dependence on key personnel and management team.

What Are the Growth Opportunities for PAVM?

• Expansion of EsoCheck and EsoGuard Market: The market for early esophageal cancer detection is substantial, with a growing emphasis on preventive screening. PAVmed can capitalize on this trend by increasing awareness and adoption of EsoCheck and EsoGuard among gastroenterologists and primary care physicians. The company can also pursue partnerships with healthcare systems and payers to expand access to these diagnostic tools. The global esophageal cancer diagnostics market is projected to reach $2.5 billion by 2030, presenting a significant growth opportunity for PAVmed.
• Commercialization of CarpX: Carpal tunnel syndrome affects millions of people worldwide, creating a large market for effective treatments. PAVmed's CarpX device offers a minimally invasive alternative to traditional carpal tunnel release surgery. By focusing on patient education and physician training, PAVmed can drive adoption of CarpX and capture a significant share of the carpal tunnel treatment market. The carpal tunnel release systems market is expected to reach $1.8 billion by 2028, providing a substantial growth opportunity for PAVmed.
• Advancement of PortIO: PAVmed's PortIO device addresses the need for reliable and long-term vascular access in patients requiring frequent infusions or blood draws. The intraosseous vascular access approach offers potential advantages over traditional intravenous catheters, particularly in patients with difficult venous access. By completing clinical trials and securing regulatory approval, PAVmed can position PortIO as a valuable tool for healthcare providers. The global vascular access devices market is projected to reach $5.5 billion by 2027, offering a significant growth opportunity for PortIO.
• Development of Veris Platform: The Veris platform represents PAVmed's entry into the digital health space, combining remote patient monitoring with data analytics. By integrating wearable sensors and cloud-based software, Veris aims to improve patient outcomes and reduce healthcare costs. PAVmed can leverage the Veris platform to develop new applications in areas such as cardiac monitoring and cancer care. The global remote patient monitoring market is expected to reach $30 billion by 2028, presenting a substantial growth opportunity for PAVmed.
• Strategic Partnerships and Acquisitions: PAVmed can accelerate its growth by forming strategic partnerships with other medical device companies, pharmaceutical companies, or healthcare providers. These partnerships can provide access to new markets, technologies, or distribution channels. PAVmed can also consider acquiring complementary businesses to expand its product portfolio and market presence. Strategic alliances and acquisitions can enhance PAVmed's competitive position and drive long-term value creation.

What Are PAVM's Competitive Advantages?

• Patented technologies provide exclusivity.
• First-mover advantage in certain markets.
• Proprietary designs and formulations.
• Established relationships with key opinion leaders.

What Does PAVM Do?

PAVmed Inc., founded in 2014 and headquartered in New York City, is a medical device company dedicated to developing and commercializing innovative technologies that address significant unmet medical needs. The company's initial focus was on minimally invasive devices for carpal tunnel syndrome and esophageal diseases, evolving into a broader portfolio of medical solutions. PAVmed's lead product, CarpX, is a percutaneous device designed for the treatment of carpal tunnel syndrome, offering a less invasive alternative to traditional surgery. EsoCheck is an esophageal cell collection device used for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE). EsoGuard, a bisulfite-converted next-generation sequencing DNA assay, complements EsoCheck by providing advanced diagnostic capabilities. The company's pipeline includes EsoCure, an esophageal ablation device for dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform; Veris, a cancer healthcare platform; NextVent single-use ventilators; FlexMO circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; and Solys noninvasive glucose monitoring. PAVmed aims to improve patient outcomes through innovative medical technologies.

What Products and Services Does PAVM Offer?

• Develop and commercialize medical devices.
• Focus on minimally invasive treatments.
• Provide diagnostic tools for early cancer detection.
• Offer solutions for carpal tunnel syndrome.
• Innovate in vascular access technology.
• Create remote patient monitoring platforms.

How Does PAVM Make Money?

• Develop and patent novel medical devices.
• Obtain regulatory approvals (e.g., FDA clearance).
• Manufacture and market medical devices.
• Generate revenue through device sales.

What Industry Does PAVM Operate In?

PAVmed operates in the medical device industry, a sector characterized by continuous innovation and regulatory scrutiny. The market for minimally invasive surgical devices and diagnostic tools is growing, driven by an aging population and increasing demand for less invasive procedures. PAVmed's focus on early cancer detection and carpal tunnel treatment positions it within specific segments of this market. The competitive landscape includes established medical device companies and emerging players with novel technologies. PAVmed's success depends on its ability to differentiate its products, secure regulatory approvals, and establish strong market presence.

Who Are PAVM's Key Customers?

• Hospitals and clinics.
• Physicians (e.g., gastroenterologists, surgeons).
• Patients requiring diagnostic or therapeutic procedures.
• Healthcare systems.

Company Profile

PAVmed Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in New York City, US. The company is led by CEO Lishan Aklog. PAVM has traded publicly since 2016.

Return on equity for PAVmed Inc. stands at -49.7%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -41.0%, showing how much profit it generates from its asset base. A current ratio of 2.02 indicates the company holds enough short-term assets to cover its near-term obligations.

PAVM Valuation & Market Position

With a $33.1M market cap, PAVmed Inc. sits in the micro-cap segment of the market. Relative to its peer group, PAVM's quantitative score of 17/100 is below the peer average of 75/100.

Quarterly Financial Performance: PAVmed Inc.

Revenue for PAVmed Inc. came in at $33K during Q2 2026, a 50.0% improvement versus the preceding quarter. The company recorded a net loss of $5.4M, with diluted EPS of $-0.87. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, PAVM averaged $-4.09 in diluted EPS.

PAVmed Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -9.66 places it in the distress zone, a signal of elevated financial risk.

PAVmed Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 39.0% below estimates on average.

Wall Street analysts project PAVmed Inc. revenue of about $340K for fiscal 2026, with EPS near $-3.14.

PAVM Financials

PAVM Latest News

No recent news available for PAVM.

PAVM Analyst Consensus

PAVM MoonshotScore

Common Questions About PAVM (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources